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Abstract
Resistant hypertension remains a major clinical 
problem despite the available multidrug therapy. Over 
the next decades, its incidence will likely increase 
given that it is strongly associated with older age 
and obesity. Resistant hypertension patients have 
an increased cardiovascular risk, thus effective 
antihypertensive treatment will provide substantial 
health benefits. The crosstalk between sympathetic 
nervous system and kidneys plays a crucial role in 
hypertension. It influences several pathophysiological 
mechanisms such as the central sympathetic tone, 
the sodium balance and the systemic neurohumoral 
activation. In fact, studies using several animal 
models demonstrated that the renal denervation 
prevented and attenuated hypertension in multiple 
species. Large reductions in blood pressure were 
also observed in malignant hypertension patients 
submitted to sympathectomy surgeries. However, 
these approaches had an unacceptably high rates of 
periprocedural complications and disabling adverse 
events. Recently, an innovative non-pharmacological 
therapy that modulates sympathetic activation has 
been successfully developed. Renal sympathetic 
percutaneous denervation is an endovascular procedure 
that uses radiofrequency energy to destroy the 
autonomic renal nerves running inside the adventitia of 
renal arteries. This method represents a promising new 
approach to the strategy of inhibiting the sympathetic 
nervous system. The aim of this review is to examine 
the background knowledge that resulted in the 
development of this hypertension treatment and to 
critically appraise the available clinical evidence.
© 2013 Baishideng. All rights reserved.
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Core tip: Renal percutaneous denervation allows 
modulating the central sympathetic tone and is a 
promising new approach to our old strategy of inhibiting 
sympathetic system. In this review we describe the 
pathophysiological knowledge that encouraged the 
development of this procedure. We critically examine 
the available clinical evidence of the impact of renal 
denervation on resistant hypertension. After describing 
the procedure and how to select the adequate patients, 
we discuss the future potential therapeutic roles in 
other disease conditions beyond resistant hypertension. 
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INTRODUCTION
Essential hypertension remains an important clinical 
challenge for both the individual as well as the public per-
spective[1]. Despite the several available antihypertensive 
drugs and their unquestionable beneficial effects, hyper-
tension control is still unsatisfactory[2,3]. This problem 
can be explained by several factors, such as inappropriate 
blood pressure measurement, physician inertia, poor ad-
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herence to therapy, excessive salt intake or the existence 
of  secondary causes of  hypertension[4]. Nevertheless, 
even after addressing these factors, uncontrolled hyper-
tension persists in a significant proportion of  patients. 
Resistant hypertension is defined as blood pressure that 
remains above the goal pressure despite the use of  at 
least 3 antihypertensive drugs of  different classes (one 
being a diuretic)[5]. The prevalence of  resistant hyperten-
sion varies between 8.9% in the National Health and Nu-
tritional Examination Survey and 50% in the ALLHAT 
Study[6]. Recently, in a large Spanish cohort of  treated 
hypertensive patients, 12.2% exhibited resistant hyper-
tension[7]. Over the next few decades, this incidence will 
likely increase given that it is strongly associated with 
older age and obesity[8]. The treatment of  resistant hyper-
tensive patients has not been directly studied[9]. However, 
their increased cardiovascular risk suggests that effective 
antihypertensive treatment will provide substantial health 
benefits. 
Accumulated evidence indicates that human sympa-
thetic nervous system deregulation contributes to the 
development of  arterial hypertension[10]. Sympathetic 
overactivity has been demonstrated in both essential and 
secondary forms of  hypertension patients, such as ob-
structive sleep apnea and obesity-related hypertension[11]. 
Over the last few decades, the focus of  hypertension re-
search has been the renin-angiotensin system[12]. Despite 
the indisputable efficacy and safety of  drugs that inhibit 
the renin-angiotensin axis, reducing sympathetic chronic 
activation could be important in a significant proportion 
of  uncontrolled hypertensive patients[13]. The aim of  this 
review is to critically examine the relevance of  renal sym-
pathetic denervation in hypertension treatment.
RENAL SYMPATHETIC DENERVATION: 
FROM THE BENCH TO THE BEDSIDE
Rationale for renal sympathetic denervation
On the one hand, renal sympathetic nerve fibers criti-
cally influence renal function[14]. Adrenergic fibers inner-
vate the most relevant renal structures such as the renal 
vasculature, the tubular epithelial cells throughout the 
nephron and the juxtaglomerular apparatus[15]. Increased 
renal sympathetic nerve activity results in a decrease in 
renal blood flow mediated by vasoconstriction (α1a ad-
renoceptors)[16], increased renal tubular sodium and water 
reabsorption (α1b adrenoceptors)[17,18], and an increased 
renin secretion rate (β1 adrenoceptors)[19,20]. These effects 
are dependent on the degree of  sympathetic activation 
and are considered to play an important role in the devel-
opment and maintenance of  hypertension[21]. 
On the other hand, the kidneys can also influence the 
sympathetic system activity. Renal structures are richly 
innervated with baroreceptors and chemoreceptors[22]. 
These afferent nerves respond to various stimuli such 
as renal ischemia, hypoxia and oxidative stress[23,24]. The 
afferent signaling from the kidneys is transmitted to the 
central nervous system and enhances sympathetic out-
flow[25], not only to the kidneys but also to other struc-
tures such as the heart and peripheral arterioles[26].
It has been feasible to study the sympathetic activa-
tion in hypertensive patients by using different methods 
that measure sympathetic activity, such as microneurog-
raphy[27,28], noradrenaline spillover[29,30] and heart rate vari-
ability[31]. A higher sympathetic nervous activation was 
documented in essential hypertension, obesity-related 
hypertension, end-stage renal disease hypertension and in 
obstructive sleep apnea[29,32-34]. Interestingly, multiple stud-
ies have shown that 50% of  hypertensive patients had an 
increased sympathetic activity in the kidneys and skeletal 
muscle vessels[11,28]. 
In conclusion, this crosstalk between the kidneys and 
sympathetic nerves, and its role in hypertension patho-
physiology disclosed renal nerves as an interesting poten-
tial therapeutic target. 
RENAL SYMPATHETIC DENERVATION 
Preclinical studies
The importance of  renal sympathetic nerves in hyper-
tension was suggested when its increased activity was 
described in genetically spontaneously hypertensive rats 
compared with normotensive controls[35]. Several animal 
models had been used to study the influence of  renal 
sympathetic fibers on hypertension[36]. In an experimen-
tal model of  hypertension associated with obesity, high-
fat diet-fed dogs that underwent renal denervation did 
not exhibited a significant increase in blood pressure 
compared with the sham group and had a 50% reduction 
of  sodium retention[37]. Additionally, in a chronic renal 
failure rat model, where the animals underwent a 5/6 
nephrectomy, bilateral dorsal rhizotomy prevented blood 
pressure increases. The procedure also resulted in lower 
neuroadrenergic activity in integrative central nervous 
structures[38]. It was also effective in a salt-sensitive hyper-
tension model, where renal denervation prevented blood 
pressure increase and normalized the sodium balance[39]. 
Ye et al[40] elegantly demonstrated the importance of  the 
renal sympathetic nervous system in hypertension. In this 
study, kidney damage was induced by intrarenal injection 
of  phenol in rats, which caused a persistent elevation of  
the blood pressure and an increase in norepinephrine 
secretion in the hypothalamus, even in the absence of  
renal failure. In this model, performing renal denervation 
prevented the blood pressure increase. 
The efficacy of  renal denervation in several models 
and in multiple species established the key role of  renal 
nerves in hypertension pathophysiology. 
Clinical studies
Surgical sympathectomy: Before antihypertensive 
drugs became available, the therapeutic option for severe 
or malignant hypertension was almost limited to surgi-
cal sympathectomy. Several surgical approaches with 
different degrees of  aggressiveness were undertaken, 
which determined the therapeutically effectiveness and 
the extent of  the side effects[41]. Total sympathectomy 
(or splanchnicectomy) surgeries were very aggressive and 
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were later replaced by a more conservative approaches 
consisting of  the removal of  the sympathetic ganglia 
from the 8th to the 12th vertebra[42]. Several studies in 
patients with malignant hypertension documented that 
sympathectomy surgeries were associated with substantial 
reductions in blood pressure and an increased survival 
rate[43]. Favorable changes in target organ damage were 
also confirmed[44]. However, these approaches were as-
sociated with high periprocedural complication rates and 
common adverse events such as orthostatic hypotension 
and tachycardia, intestinal disturbances, anhidrosis, and 
sexual dysfunction[45]. After the development of  pharma-
cological treatment options, these surgeries were reserved 
only for severe hypertension patients refractory to phar-
macological treatment. Surgical and renal percutaneous 
sympathectomies are quite different procedures concern-
ing the extent of  denervation in particular. Neverthe-
less, the surgical sympathectomy studies were important 
because they first demonstrated that the disruption of  
human splanchnic autonomic fibers was associated with 
significant reductions in blood pressure.
Percutaneous sympathectomy: The first clinical study 
that assessed the effect of  percutaneous sympathetic re-
nal denervation in hypertension patients was published in 
2009. Symplicity HTN-1[46] was a safety and proof-of-prin-
ciple cohort study that enrolled 45 patients (mean age 58 
± 9 years) with resistant hypertension (defined as systolic 
blood pressure > 160 mmHg despite the use of  at least 3 
antihypertensive drugs, including a diuretic). These patients 
underwent a bilateral application of  radiofrequency to the 
renal arteries. The office blood pressures after the proce-
dure were reduced by 14/10 mmHg at 1 mo and 27/17 
mmHg at 12 mo. No favorable change in blood pressure 
occurred in 13% of  patients. This antihypertensive effect 
is sustained at least up to 24 mo after the procedure[47]. 
Additionally, a significant reduction (42%) in renal and 
total body norepinephrine spillover was observed in a 
small subgroup of  the patients who underwent sympa-
thetic activity measurements[46]. 
This cohort study was followed by a multicentre, pro-
spective, randomized trial named Symplicity HTN-2 tri-
al[48] published in 2010. One hundred and six patients with 
resistant hypertension were randomly allocated to renal 
denervation plus conventional antihypertensive drugs ver-
sus antihypertensive drugs only. The primary end-point 
was an office systolic blood pressure at the 6-mo follow-
up visit. The office blood pressure in the catheter-based 
sympathectomy group indicated a reduction of  32/12 
mmHg at the end of  this period. The home and ambula-
tory blood pressure confirmed the observed office blood 
pressure changes falling by 20/12 and 11/7 mmHg, re-
spectively, at 6 mo. No blood pressure changes occurred 
in the control group. At 12-mo follow-up, the magnitude 
of  clinical response was sustained[49]. Although these 
trials have shown a significant blood pressure overall 
reduction, 13% (n = 6) and 10% (n = 5) of  patients that 
underwent renal denervation had no decrease in systolic 
blood pressure in Symplicty HTN-1 and Simplicity 
HTN-2, respectively. No predictor of  nonresponse was 
found in univariate analysis of  these patients’ clinical 
and procedural characteristics. We can speculate that the 
procedure might have failed to obtain an adequate renal 
denervation. Another hypothetical explanation is the 
heterogeneous contribution of  sympathetic activity to 
hypertension pathophysiology. The identification of  the 
appropriate candidates to renal denervation is a challenge 
that should be answered by forthcoming studies. Recently, 
the published interventional and observational studies on 
renal denervation have been systematically reviewed[50]. 
All studies reported significant reductions in blood pres-
sure of  resistant hypertension patients.
Brandt et al[51] demonstrated that renal denervation 
in resistant hypertension patients was associated with a 
regression of  left ventricle hypertrophy and an improve-
ment of  the diastolic function at 6-mo follow-up visit, 
compared with the control group. Interestingly, a signifi-
cant decrease in the left ventricular mass was also ob-
served in patients who did not have a significant decrease 
in blood pressure. 
CRITICAL APPRAISAL OF TREATMENT 
STUDIES RESULTS
The results of  the Symplicity trials are promising. Never-
theless, several limitations must be considered. Symplicity 
HTN-2 was an open-label trial, which means that the 
physician who performed the blood pressure measure-
ment was not blinded to the type of  treatment. There-
fore, we cannot rule-out an ascertainment bias. In addi-
tion, there was no sham procedure in the control group, 
thus we cannot measure the extent of  the placebo effect. 
The effect of  treatment in the office blood pressure was 
concordant but more pronounced than the ambulatory 
blood pressure. Although this observation could repre-
sent a higher sympathetic activation with the office blood 
pressure measurement than during ambulatory moni-
toring, this discrepancy needs further elucidation. The 
small number of  patients, the short period of  follow-up 
and the absence of  studies with hard clinical end-points 
precludes the establishment of  the true antihypertensive 
effect and its prognostic importance. Some of  these limi-
tations will be addressed by the Symplicity HTN-3 trial[52]. 
This prospective, masked procedure, single-blind trial will 
randomize 530 patients and will include as a major sec-
ondary end-point, the change in the average 24-h systolic 
blood pressure by ambulatory blood pressure monitoring. 
SAFETY DATA
In the larger cohort of  patients that underwent percuta-
neous renal denervation (n = 153)[47], 97% experienced 
no complications. The four procedural complications in-
cluded three pseudoaneurysm-hematomas in the arterial 
access site and one renal artery dissection that occurred 
before radiofrequency energy delivery in that artery. They 
were all managed without any long-term sequelae. The 
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like organization inside the adventitia. This destruction is 
accomplished by inserting a catheter capable of  delivering 
radiofrequency energy into the renal artery lumen. First, 
a guide catheter is engaged in the renal artery osteum by 
femoral percutaneous access. Then, a catheter specifically 
designed for renal denervation[54] (Symplicity, Ardian, 
Palo Alto, CA, United States) is introduced into the renal 
artery. The tip of  the catheter has an electrode that is po-
sitioned, under fluoroscopic guidance (Figure 1), in con-
tact with the artery wall to deliver low-power (less than 8 
watts) radiofrequency energy for short time intervals (up 
to 2 min). During ablation, the catheter system continual-
ly monitors the temperature and impedance to adjust the 
energy that is being delivered (Figure 2). The procedure 
elicits abdominal visceral pain that can be managed with 
analgesic and sedative drugs. The denervation requires up 
to six separate ablations, longitudinally and circumferen-
tially in each renal artery. The duration of  this minimally 
invasive procedure is approximately 45 min. 
Starting a program of percutaneous renal denervation: 
our experience
We deal with an increasing number of  resistant hyper-
tension patients during our daily clinical activity. When 
general measures and drug therapy optimization fail to 
control hypertension, we then consider another treatment 
option for our patients. The implementation of  our per-
cutaneous renal denervation program was governed by 
two main concerns: minimizing the risk of  the procedure 
small number of  procedures does not allow a strong con-
clusion to be made about the periprocedural safety of  re-
nal percutaneous denervation. Nevertheless, considering 
that the technique and the diameter of  catheters are the 
same of  coronary angiography, local femoral artery com-
plications will likely have an incidence similar to coronary 
interventional procedures. In Symplicty HTN-2[48], there 
was one pseudoaneurysm-hematoma and no other major 
complication. Although the intensity of  the radiofrequen-
cy energy is lower than the one used for pulmonary vein 
isolation in atrial fibrillation ablation, renal artery stenosis 
is a concern. In Symplicity HTN-2, 43 of  49 patients in 
the intervention group underwent renal artery imaging 
at the 6-mo follow-up, and no significant stenosis was 
diagnosed. Regarding renal function, the estimated glo-
merular filtration rate was stable up to 24 mo of  follow-
up[47,53]. 
The available evidence from clinical studies reveals 
that catheter-based renal denervation has an excellent 
short-term safety profile. Although unlikely, a risk of  re-
nal artery stenosis during long-term follow-up cannot be 
excluded. 
RENAL SYMPATHETIC DENERVATION: 
FROM TRIALS TO REAL LIFE
Description of the procedure
The purpose of  catheter-based renal sympathetic nerve 
ablation is to destroy the renal nerves that form a mesh-
BA
Figure 1  Left renal artery angiogram showing the catheter 
inside the artery. 
BA
Figure 2  The Symplicity catheter and the radiofrequency console. 
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and selecting the adequate patients. 
How to minimize the risk of the procedure? 
Despite the simplicity of  this minimally invasive tech-
nique, an experienced interventional cardiologist per-
forms the procedure. In addition to the skills needed to 
deal with arterial access, the certified training in this spe-
cific technique is important to assure a safe and efficient 
procedure. We also collaborate with an anesthesiologist, 
which is extremely helpful in managing the visceral pain 
commonly induced during the radiofrequency ablation. 
Our patients remain in the hospital for 24 h after the pro-
cedure for clinical monitoring. After discharge, we sched-
ule clinical appointments at one, three, six and twelve 
months after the intervention. 
How to select the patients?
Based on the available clinical studies, adult hypertensive 
patients are eligible for renal denervation if  they have a 
systolic blood pressure of  160 mmHg or more (> 150 
mmHg in patients with type 2 diabetes) despite treatment 
with three or more antihypertensive drugs, including one 
diuretic. Patients are not candidates for renal denervation 
if  they have a renal artery anatomy that precludes treat-
ment such as a diameter less than 4 mm, length less than 
20 mm or the presence of  more than one main renal 
arteries (Figure 3). Another exclusion criterion is an esti-
mated glomerular filtration rate of  less than 45 mL/min 
per 1.73 m2. 
Before assessing whether patients meet the inclusion 
or exclusion criteria for the clinical studies, we evaluate 
the patients according to a clinical protocol[9,55]. First, we 
exclude those with pseudoresistance hypertension by re-
peating office blood pressure measurements, and we rule-
out the common white-coat effect with an ambulatory 
blood pressure monitoring. Then, we screen for second-
ary causes of  hypertension and, subsequently, confirm an 
adequate treatment regimen (up titrate to maximum toler-
ated doses) and patient adherence. If  the blood pressure 
is still not controlled, we prescribe other agents as needed 
and tolerated such as beta-blockers, chlorthalidone or 
furosemide, spironolactone, and/or centrally acting sym-
pathetic suppressants. At the end of  this work-up, if  the 
blood pressure is higher than the target goals, we assess 
the patient eligibility criteria for renal denervation.
FUTURE PERSPECTIVES
This new treatment explores a revolutionary principle 
that allows the modulation of  the sympathetic central 
tone and can have a beneficial role in cardiovascular dis-
eases beyond resistant hypertension[56,57]. Renal denerva-
tion has the potential of  being beneficial in milder forms 
of  hypertension[58] or secondary forms such as end-stage 
renal disease-related hypertension[59,60] where sympathetic 
overactivity has been demonstrated. Insulin sensitivity 
was improved in essential hypertensive[61] and obstructive 
sleep apnea-related hypertension patients[62], revealing 
a potential role in metabolic syndrome management[63]. 
The maladaptive role of  the chronic activation of  the 
sympathetic nervous system is a well-known hallmark of  
heart failure pathophysiology[64]. Clinical studies with re-
nal sympathetic denervation in heart failure patients are 
currently being performed[65,66]. We are tempted to spec-
ulate on the potential therapeutic role of  renal denerva-
tion in other diseases such as hepatorenal syndrome and 
polycystic ovary syndrome[67]. Selective renal sympathetic 
denervation is a novel and promising technique that 
opened a new window of  opportunities that deserve to 
be explored.
CONCLUSION
Over the last few decades, growing knowledge about 
the role of  the sympathetic chronic activation in the 
pathophysiology of  hypertension has resulted in the de-
velopment of  the catheter-based renal sympathetic nerve 
ablation. This minimally invasive procedure pursues the 
efficacy of  surgical sympathectomy and the safety of  
drug therapy. So far, clinical studies have demonstrated 
impressive and consistent blood-pressure reductions 
in resistant hypertensive patients. We acknowledge that 
there is still a lack of  evidence from large placebo-
controlled randomized clinical trials that are currently 
being conducted. Nevertheless, considering the available 
efficacy and safety data, renal percutaneous denervation 
should be considered for carefully selected patients with 
resistant hypertension.
BA
Figure 3  Computed tomography angiography re-
vealing normal renal arteries of a resistant hyperten-
sion patient. 
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